Mechanism and clinical significance of HBV reactivation after anti-HCV therapy.
10.3760/cma.j.cn501113-20200831-00485
- Author:
Wan Jia ZENG
1
;
Lin GAO
2
;
Yi Wei XU
1
;
Xiang Mei CHEN
1
;
Fu Sheng WANG
3
;
Feng Min LU
4
Author Information
1. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
2. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China Peking University 302 Clinical Medical School, Beijing 10039, China.
3. Peking University 302 Clinical Medical School, Beijing 10039, China Treatment and Research Center for Infectious Diseases, the Fifth Medical Centre of Chinese PLA (People's Liberation Army) General Hospital, Beijing 100039, China.
4. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Hepatitis B virus;
Hepacivirus;
Antiviral Agents/pharmacology*;
Hepatitis C, Chronic/drug therapy*;
Virus Activation;
Hepatitis C/drug therapy*;
Coinfection/drug therapy*;
Hepatitis B/drug therapy*
- From:
Chinese Journal of Hepatology
2022;30(9):997-1001
- CountryChina
- Language:Chinese
-
Abstract:
Direct-acting antivirals (DAAs) can strongly inhibit the replication of hepatitis C virus (HCV) and effectively clear the infection, but it may cause hepatitis B virus (HBV) reactivation, leading to severe liver damage and fulminate hepatitis in patients with HCV/HBV coinfection. In this review, we summarized the different replication process of HCV and HBV in infected hepatocytes and consequent innate immune response, and then discussed the molecular mechanism and clinical significance of HBV reactivation, and put forward the clinical precaution.
